Compare Stocks: GHRS, LNTH, BLTE, and LQDA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$151.72	$156.25	$62.18 ▼ $200.00	$6.08B	-1.22	168,056 shs	171,257 shs
GHRS GH Research	$27.94	$27.85	$11.83 ▼ $31.44	$1.92B	1.29	312,059 shs	117,661 shs
LNTH Lantheus	$100.77	$103.74	$49.67 ▼ $111.86	$6.58B	-0.03	2.16 million shs	1.14 million shs
LQDA Liquidia	$67.69	$79.27	$21.15 ▼ $93.61	$6.06B	0.58	1.54 million shs	926,261 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	0.00%	-5.80%	-4.34%	+3.21%	+140.71%
GHRS GH Research	0.00%	-1.38%	-0.46%	+12.53%	+106.96%
LNTH Lantheus	0.00%	+0.80%	+1.13%	+3.75%	+83.55%
LQDA Liquidia	0.00%	-1.36%	-19.52%	+15.24%	+144.54%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$151.72	$156.25	$62.18 ▼ $200.00	$6.08B	-1.22	168,056 shs	171,257 shs
GHRS GH Research	$27.94	$27.85	$11.83 ▼ $31.44	$1.92B	1.29	312,059 shs	117,661 shs
LNTH Lantheus	$100.77	$103.74	$49.67 ▼ $111.86	$6.58B	-0.03	2.16 million shs	1.14 million shs
LQDA Liquidia	$67.69	$79.27	$21.15 ▼ $93.61	$6.06B	0.58	1.54 million shs	926,261 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	0.00%	-5.80%	-4.34%	+3.21%	+140.71%
GHRS GH Research	0.00%	-1.38%	-0.46%	+12.53%	+106.96%
LNTH Lantheus	0.00%	+0.80%	+1.13%	+3.75%	+83.55%
LQDA Liquidia	0.00%	-1.36%	-19.52%	+15.24%	+144.54%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	2.63	Moderate Buy	$205.80	35.64% Upside
GHRS GH Research	2.75	Moderate Buy	$45.00	61.06% Upside
LNTH Lantheus	2.29	Hold	$108.11	7.29% Upside
LQDA Liquidia	2.45	Hold	$98.08	44.90% Upside

Current Analyst Ratings Breakdown

Latest GHRS, LNTH, BLTE, and LQDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/18/2026	BLTE Belite Bio	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/17/2026	LNTH Lantheus	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/14/2026	BLTE Belite Bio	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$201.00 ➝ $206.00
8/14/2026	BLTE Belite Bio	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	BLTE Belite Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$220.00
8/13/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
8/13/2026	LQDA Liquidia	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$106.00
8/13/2026	LQDA Liquidia	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$62.00 ➝ $108.00
8/13/2026	GHRS GH Research	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/13/2026	LQDA Liquidia	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$20.54 per share	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	$4.51 per share	N/A
LNTH Lantheus	$1.54B	4.27	$6.39 per share	15.78	$16.43 per share	6.13
LQDA Liquidia	$158.32M	38.27	N/A	N/A	$0.51 per share	132.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$77.61M	-$2.73	N/A	166.73	N/A	N/A	-11.84%	-11.62%	11/9/2026 (Estimated)
GHRS GH Research	-$48.26M	-$1.00	N/A	N/A	N/A	N/A	-20.86%	-20.12%	11/5/2026 (Estimated)
LNTH Lantheus	$233.56M	$4.14	24.34	18.63	N/A	17.69%	28.10%	14.35%	11/5/2026 (Estimated)
LQDA Liquidia	-$68.92M	$1.37	49.41	15.45	N/A	30.74%	149.65%	36.30%	11/2/2026 (Estimated)

Latest GHRS, LNTH, BLTE, and LQDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	BLTE Belite Bio	-$0.73	-$0.54	+$0.19	-$0.70	N/A	N/A
8/12/2026	Q2 2026	LQDA Liquidia	$0.7580	$0.74	-$0.0180	$0.74	$168.48 million	$171.68 million
8/6/2026	Q2 2026	GHRS GH Research	-$0.2860	-$0.23	+$0.0560	-$0.23	N/A	N/A
8/6/2026	Q2 2026	LNTH Lantheus	$1.30	$1.55	+$0.25	$1.11	$363.23 million	$388.18 million
6/30/2026	Q2 2026	BLTE Belite Bio	N/A	-$0.54	N/A	-$0.70	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	33.56	33.56
GHRS GH Research	N/A	28.70	28.70
LNTH Lantheus	0.43	3.06	2.89
LQDA Liquidia	0.63	2.31	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
GHRS GH Research	56.90%
LNTH Lantheus	99.06%
LQDA Liquidia	64.54%

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
GHRS GH Research	N/A
LNTH Lantheus	1.70%
LQDA Liquidia	25.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	10	40.09 million	34.92 million	Not Optionable
GHRS GH Research	10	68.61 million	N/A	Optionable
LNTH Lantheus	1,193	65.27 million	64.16 million	Optionable
LQDA Liquidia	50	89.51 million	66.60 million	Optionable

GHRS, LNTH, BLTE, and LQDA Headlines

Recent News About These Companies

Bank of New York Mellon Corp Makes New Investment in Liquidia Corporation $LQDA

August 30 at 3:19 AM | marketbeat.com

Liquidia Corp (LQDA) Stock Down 3.1% -- Now Undervalued? GF Score: 70/100

August 28 at 11:00 PM | gurufocus.com

Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?

August 27, 2026 | zacks.com

Liquidia Corporation $LQDA Shares Bought by Seven Fleet Capital Management LP

August 27, 2026 | marketbeat.com

Liquidia (NASDAQ:LQDA) Insider Jason Adair Sells 73,631 Shares of Stock

August 25, 2026 | marketbeat.com

Will LQDA's Differentiated PAH Approach Drive Growth?

August 24, 2026 | zacks.com

Liquidia (NASDAQ:LQDA) Director Sells $2,758,807.11 in Stock

August 24, 2026 | americanbankingnews.com

Katherine Rielly-Gauvin Sells 18,393 Shares of Liquidia (NASDAQ:LQDA) Stock

August 22, 2026 | insidertrades.com

Katherine Rielly-Gauvin Sells 18,393 Shares of Liquidia (NASDAQ:LQDA) Stock

August 21, 2026 | marketbeat.com

Liquidia (NASDAQ:LQDA) Director Katherine Rielly-Gauvin Sells 36,789 Shares of Stock

August 21, 2026 | marketbeat.com

Liquidia Corp (LQDA) Shares Fall 5.8% -- What GF Score of 70 Tells Investors

August 20, 2026 | gurufocus.com

Liquidia (NASDAQ:LQDA) Insider Rajeev Saggar Sells 29,534 Shares

August 20, 2026 | insidertrades.com

Liquidia (LQDA) Q2 2026 Earnings Call Transcript

August 19, 2026 | finance.yahoo.com

Liquidia (NASDAQ:LQDA) Insider Rajeev Saggar Sells 29,534 Shares of Stock

August 19, 2026 | marketbeat.com

Liquidia (NASDAQ:LQDA) Insider Sells $3,703,000.00 in Stock

August 19, 2026 | marketbeat.com

Can Yutrepia's Strong Growth Drive Liquidia's PAH Expansion?

August 19, 2026 | zacks.com

Renaissance Technologies LLC Sells 198,753 Shares of Liquidia Corporation $LQDA

August 19, 2026 | marketbeat.com

Handelsbanken Fonder AB Invests $1.99 Million in Liquidia Corporation $LQDA

August 18, 2026 | marketbeat.com

LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now?

August 17, 2026 | zacks.com

FY2026 EPS Estimates for Liquidia Reduced by HC Wainwright

August 17, 2026 | marketbeat.com

Liquidia (NASDAQ:LQDA) Rating Lowered to "Hold" at Zacks Research

August 15, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS, LNTH, BLTE, and LQDA Company Descriptions

Belite Bio NASDAQ:BLTE

$151.72 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

GH Research NASDAQ:GHRS

$27.94 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Lantheus NASDAQ:LNTH

$100.77 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Liquidia NASDAQ:LQDA

$67.69 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GHRS, LNTH, BLTE, and LQDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GHRS, LNTH, BLTE, and LQDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GHRS, LNTH, BLTE, and LQDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS, LNTH, BLTE, and LQDA Company Descriptions

Belite Bio NASDAQ:BLTE

GH Research NASDAQ:GHRS

Lantheus NASDAQ:LNTH

Liquidia NASDAQ:LQDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GHRS, LNTH, BLTE, and LQDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GHRS, LNTH, BLTE, and LQDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GHRS, LNTH, BLTE, and LQDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS, LNTH, BLTE, and LQDA Company Descriptions

Belite Bio NASDAQ:BLTE

GH Research NASDAQ:GHRS

Lantheus NASDAQ:LNTH

Liquidia NASDAQ:LQDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools